arrow
M

Michał Brzdęk

Jan Kochanowski University
H指数:10
被引数:292

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study

直接抗病毒药物对合并高血压的丙型肝炎患者是否有效且安全?——来自一项大型回顾性真实世界研究的结果

2026-08-230
OA
Does rheumatoid arthritis affect the course of chronic hepatitis C and outcomes of antiviral treatment?

类风湿关节炎是否影响慢性丙型肝炎的病程及抗病毒治疗效果?

2026-05-281
PRE
Predictors of Severe Outcomes in COVID-19: Evidence from Real-World Multicenter Retrospective Study (2020–2024)

新型冠状病毒肺炎严重结局的预测因素: 来自真实世界多中心回顾性研究的证据 (2020-2024)

2026-02-040
OAAI
Differences in the Clinical Course of COVID-19 in Patients Hospitalized in the 2023-2024 and 2024-2025 Seasons

2023-2024和2024-2025季节住院患者中COVID-19临床病程的差异

2025-08-250
PRE
Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination(vol 22, 486, 2024)

抗病毒治疗后患者的随访损失作为HCV消除的额外障碍 (第22卷,486,2024)

2024-11-080
OAAI
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices

HCV感染的肝硬化和食管静脉曲张患者直接抗病毒治疗的真实世界经验

2024-08-201
OAAI
Hepatitis B virus coinfection in patients treated for chronic hepatitis C: clinical characteristics, risk of reactivation with long-term follow-up and effectiveness of antiviral therapy

治疗慢性丙型肝炎患者的乙型肝炎病毒合并感染: 临床特征,长期随访的再激活风险和抗病毒治疗的有效性

2024-01-023
OA
Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
2023-04-0711
OAAI